ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE
AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE
CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE
CHLORPHENIRAMINE MALEATE; IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE
CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR
DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR
EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE
FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL
GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE
MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE
MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE
SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES

CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER
CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE
EFAVIRENZ, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE
EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE
ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER
ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER
LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE
LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

IRRITABLE BOWEL SYNDROME WITH CONSTIPATION
MODERATE OR SEVERE SUBMENTAL FULLNESS (FAT BELOW THE CHIN)
NEUROPATHIC PAIN FROM POST-HERPETIC NEURALGIA (PHN)
REVERSAL OF NEUROMUSCULAR BLOCKADE INDUCED BY ROCURONIUM OR VECURONIUM
SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME(LGS)

<=2 WATERY STOOLS PER WEEK FOR AT LEAST 2 OF 4 WEEKS
>= 2-GRADE DECREASE IN CLINICIAN ERYTHEMA ASSESSMENT (CEA) AND SUBJECT SELF-ASSESSMENT (SSA)
>= 2 MM OF NEW CLEAR NAIL GROWTH + NEGATIVE FUNGAL CULTURE
15 LETTER IMPROVEMENT VISUAL ACUITY (BCVA)
20 PCT IMPROVEMENT SPONDYLOARTHRITIS SOCIETY SCORE
AMERICAN COLLEGE OF RHEUMATOLOGY 20% (ACR20) RESPONSE
ANNUALIZED MULTIPLE SCLEROSIS RELAPSE RATE
CFB 24-HOUR AVERAGE PAIN INTENSITY (API) SCORE
CFB ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT)
CFB COMPLETE SPONTANEOUS BOWEL MOVEMENT ONE WEEK (CSBM) RATE
CFB IN PERCENT PREDICTED FORCED VITAL CAPACITY (FVC)
CFB IN SUBMENTAL FAT (SMF) RATING SCALE SCORE
CFB INTERNATIONAL PROSTATE SYMPTOM SCORE
CFB PERCENT PARABASAL CELLS IN VAGINAL SMEAR
CFB PSORIASIS AREA AND SEVERITY INDEX SCORE
CFB SATISFYING SEXUAL EVENT MONTH OF FINAL VISIT
CFB SEATTLE ANGINA QUESTIONNAIRE ANGINA FREQUENCY
CFB ST. GEORGES RESPIRATORY QUESTIONNAIRE
CFB TOTAL MOTOR ABNORMAL INVOLUNTARY MOVEMENT SCALE (AIMS)
CLINICAL REMISSION IRRITABLE BOWEL DISEASE
DECREASE IN OVERALL TARGET PLAQUE SEVERITY SCORE (OTPSS)
IMPROVEMENT IN ATOPIC DERMATITIS SEVERITY INDEX
INVESTIGATOR GLOBAL ASSESSMENT CLEAR/ALMOST CLEAR
MEDIAN PCFB SEIZURE FREQUENCY (NUMBER/28 DAYS)
MEDIAN PCFB WALKING SPEED ON 25-FOOT WALK
NUMBER OF NEW GDE LESIONS THROUGH WEEK 24
PCFB BONE MINERAL DENSITY AT LUMBAR SPINE
PCT COMPLETE SPONTANEOUS BOWEL MOVEMENT (SBM)
PCT REPONDERS IN  ABDOMINAL PAIN AND DAILY STOOL CONSISTENCY SCORES
PHYSICIAN GLOBAL ASSESSMENT ARTHRITIS PAIN
PROPORTION OF SUBJECTS WITH AN SUA LEVEL THAT IS < 6.0 MG/DL
PSORIASIS AREA AND SEVERITY INDEX SCORE>=75% REDUCTION
REFLEX EPILEPSY STANDARDIZED PHOTOSENSITIVITY RANGE
SEIZURE FREQUENCY(NUMBER/28 DAYS) <50% BASELINE
TIME FROM START OF ADMINISTRATION OF STUDY TREATMENT (SUGAMMADEX OR PLACEBO) TO RECOVERY T4/T1 RATIO TO 0.9
TOTAL NUMBER OF GDE LESIONS THROUGH WEEK 24
WEEKLY AVERAGE INCREASE IN HEMOGLOBIN LEVEL
WEEKLY NORMALIZED COMPLETE SPONTANEOUS BOWEL MOVEMENT (CSBM) RATE
WEEKLY NORMALIZED SPONTANEOUS BOWEL MOVEMENT (SBM) FREQUENCY